Zobrazeno 1 - 10
of 25
pro vyhledávání: '"E. Dokukina"'
Autor:
Vladimir V. Popov, Yulia N. Linkova, Arina V. Zinkina-Orikhan, Bulat A. Bakirov, Olga M. Moiseeva, Maria A. Morozova, Nikita V. Lomakin, E. Dokukina, A. Eremeeva, Elena S. Pasechnik, Anton A. Lutckii, Mikhail Yu Gilyarov, Mazurov Vi, Anton I. Seleznev, Polina S. Pukhtinskaia, Gaziyavdibir H. Musaev, Elena A Smolyarchuk, Denis N. Protsenko, Dar'ya S. Fomina, Ivan G. Gordeev
Publikováno v:
Inflammation Research
Objective and design The aim of this double-blind, placebo-controlled, phase III CORONA clinical trial was to evaluate the efficacy and safety of IL-6 receptor inhibitor levilimab (LVL) in subjects with severe COVID-19. Subjects The study included 21
Autor:
N. Lomakin, D. Protsenko, O. Moiseeva, D. Fomina, V. Mazurov, M. Morozova, E. Dokukina, D. Bogdan, A. Lutskii, Ivan G. Gordeev, A. Seleznev, V. Popov, Elena A Smolyarchuk, G. Musaev, B. Bakirov, I. Linkova, E. Pasechnik, M. Gilyarov, A. Zinkina-Orihan
Publikováno v:
Annals of the Rheumatic Diseases. 80:890-891
Background:Levilimab (LVL) is a novel anti-IL6Rmonoclonal antibody against IL6Rα. Cytokine release syndrome plays the key role in the pathogenesis of a range of life-threatening conditions including the acute respiratory distress syndrome in severel
Autor:
A. Kastanayan, Maxim Aleksandrovich Korolev, N. Soroka, V. Mazurov, A. Kundzer, S. Smakotina, O. Tciupa, A. Zinkina-Orihan, T. Kropotina, T. Povarova, T. Raskina, T. Popova, T. Plaksina, D. Kretchikova, A. Lutskii, O. Nesmeyanova, E. Dokukina, O. Antipova, A. Plotnikova
Publikováno v:
Annals of the Rheumatic Diseases. 80:550-551
Background:Previously, the results of phase II AURORA clinical study of levilimab in subjects with active rheumatoid arthritis (RA) have been reported1. Here we report topline 24-weeks results of preliminary primary efficacy and safety analysis of ph
Autor:
A. V. Samtsov, M. Kokhan, V. Khayrutdinov, N. Soroka, A. Bakulev, A. Kundzer, Inna Gaydukova, A. Eremeeva, T. Korotaeva, E. Dokukina, V. Mazurov
Publikováno v:
Annals of the Rheumatic Diseases. 79:141-142
Background:Netakimab (NTK) is a humanized anti-interleukin 17A antibody approved for the treatment of moderate-to-severe plaque psoriasis.Objectives:To determine the efficacy and safety of NTK in patients (pts) with active psoriatic arthritis (PsA),
Autor:
N. Soroka, A. Bakulev, Inna Gaydukova, A. V. Samtsov, V. Mazurov, M. Kokhan, A. Eremeeva, T. Korotaeva, V. Khayrutdinov, A. Kundzer, E. Dokukina
Publikováno v:
Annals of the Rheumatic Diseases. 79:1695-1696
Background:Psoriatic arthritis (PsA) is associated with multiple manifestations, resulting in reduced health-related quality of life (HR-QoL) of patients (pts). Netakimab (NTK) is a humanized anti-IL17A antibody approved for the treatment of moderate
Autor:
N. Soroka, Evgeniy Zotkin, T. Kropotina, Vadim I. Mazurov, A. Kundzer, Elena Ilivanova, E. Chernyaeva, Anton Lutskii, O. Nesmeyanova, E. Dokukina, Roman Ivanov, T. Plaksina
Publikováno v:
Poster Presentations.
Background: In the previous phase 1 study BCD-089 (INN: levilimab) was well-tolerated, had favorable safety profile and low immunogenicity1. Here we report 12-week efficacy and safety results of ongoing phase 2 clinical study of BCD-089 in patients w
Autor:
E. Dokukina, Vadim I. Mazurov, Elena Ilivanova, N. Soroka, E. Chernyaeva, Roman Ivanov, O. Nesmeyanova, Tatiana Dubinina, A. Eremeeva, A. Kundzer, Inna Gaydukova, Shandor Erdes
Publikováno v:
Spondyloarthritis – treatment.
Background chronic pain, stiffness, fatigue and limited spinal mobility significantly affect quality of life (QoL) in patients (pts) with axial spondyloarthritis (axSpA). There is increasing evidence that IL-17 blockade is highly effective in this pt
Autor:
Elena P Ilivanova, Julia Valentinovna Usacheva, L. Denisov, Roman A. Ivanov, O. Nesmeyanova, Alexander Lila, E. Chernyaeva, A. Eremeeva, E. Dokukina, Mazurov Vi
Publikováno v:
Rheumatology international. 39(9)
BCD-055 is a biosimilar of innovator infliximab (IFX). Here we present the 54-week results from phase 3 clinical study in patients with rheumatoid arthritis (RA). The aim of this study was to demonstrate the equivalent efficacy and safety of BCD-055
Autor:
A E Dokukina, V.P. Kandidov
Publikováno v:
Journal of Russian Laser Research. 36:577-587
We investigate the propagation of a femtosecond wave packet focused by an axicon in the linear medium. We introduce a scaling parameter for the problem of the Bessel–Gaussian beam formation in the femtosecond light. This parameter is based on a mul
Autor:
N. Soroka, A. Bakulev, A. Kundzer, V. Khayrutdinov, T. Korotaeva, E. Dokukina, A. Eremeeva, V. Mazurov, M. Kokhan, A. V. Samtsov, Inna Gaydukova
Publikováno v:
Annals of the Rheumatic Diseases. 79:1694.2-1695
Background:Patients with psoriatic arthritis (PsA) have skin manifestations that negatively affect their quality of life. Netakimab (NTK) is a humanized anti-interleukin 17A antibody approved for the treatment of moderate-to-severe plaque psoriasis.O